Adult Vaccine Market: Trends, Analysis & Forecast (2025-2033)

Adult Vaccine Market Global Forecast Report (2024-2032) – Disease-Wise and Country Analysis

Market Overview

The global adult vaccine market was valued at US$ 20.59 billion in 2023 and is projected to grow to US$ 35.87 billion by 2032, registering a CAGR of 6.36% from 2024 to 2032. The increasing prevalence of vaccine-preventable diseases such as pneumococcal illness, influenza, COVID-19, and others is expected to drive the demand for adult immunizations worldwide. Government and nonprofit initiatives promoting immunization and increasing healthcare awareness are significant contributors to this growth.

Download Sample: https://www.renub.com/request-sample-page.php?gturl=adult-vaccines-market-company-adult-vaccines-sales-country-adult-vaccines-worldwide-analysis-19-p.php

Adult Vaccine Market Segmentation

The adult vaccine market is segmented based on disease type, country, and key industry players.

Disease-Wise Market Segmentation:

• Influenza – Seasonal influenza vaccinations remain critical, particularly for high-risk groups such as the elderly, healthcare workers, and individuals with chronic diseases.
• Cervical Cancer (HPV) – Increasing awareness of HPV-related cancers is driving HPV vaccine adoption.
• Zoster (Shingles) – Rising incidences of shingles among aging populations support market expansion.
• MMR (Measles, Mumps, and Rubella Vaccine) – Ongoing efforts to eliminate measles outbreaks fuel the demand.
• Pneumococcal – Pneumococcal vaccinations are essential for reducing pneumonia and other respiratory illnesses.
• Meningococcal – Targeted vaccination programs are contributing to market growth.
• Hepatitis – Hepatitis A and B vaccinations continue to be crucial for liver disease prevention.
• Tdap (Tetanus, Diphtheria, and Pertussis) – Routine adult booster shots drive steady market demand.
• Travel and Miscellaneous Vaccines – Increasing international travel is boosting demand for region-specific vaccines.
• Varicella – The need to prevent chickenpox among adults supports its market growth.

Regional Market Analysis:

The adult vaccine market is analyzed across 21 major countries, including:

North America

• United States
• Canada

Europe

• United Kingdom
• Germany
• France
• Russia
• Italy
• Spain
• Switzerland

Asia Pacific

• India
• China
• Japan
• Australia
• South Korea

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• United Arab Emirates
• South Africa
• Rest of the World

Market Growth Factors

1. Increasing Prevalence of Adult Diseases

As life expectancy rises, so does the risk of age-related diseases. Unlike pediatric diseases that are controlled through routine immunization, adults remain vulnerable to influenza, shingles, pneumonia, and hepatitis, necessitating periodic booster vaccinations.

According to the CDC, influenza and its complications caused over 75,000 hospitalizations and 5,000 fatalities in the United States (2019–2020). Similarly, WHO reports that Streptococcus pneumoniae is responsible for 500,000 deaths annually.

2. Growing Awareness and Government Initiatives

Governments worldwide are launching campaigns to increase adult immunization rates. For example, the U.S. Centers for Disease Control and Prevention (CDC) recommends annual flu shots for all adults, along with Tdap booster shots every ten years.

3. Expansion in Vaccine Development and Approvals

The global adult vaccine market is poised for significant growth with the introduction of new vaccines. For instance:

• GSK’s Arexvy (May 2023) – The first respiratory syncytial virus (RSV) vaccine for adults over 60, approved by the U.S. FDA.
• Merck’s 21-valent pneumococcal conjugate vaccine (V116) (April 2024) – Phase 3 trials demonstrated its efficacy compared to PPSV23.
• Moderna’s mRNA-based influenza vaccine (mRNA-1010) – Expected to revolutionize flu immunization with enhanced efficacy.

North America: Leading the Adult Vaccine Market

North America is the dominant region in the global adult vaccine market due to high adult immunization rates, strong government policies, and technological advancements. According to the National Institutes of Health (NIH), influenza vaccinations prevent nearly 90,000 hospitalizations annually in the U.S.

The CDC recommends that adults receive immunizations for seasonal influenza, pneumococcal diseases, herpes zoster, and Tdap. This strong policy framework continues to propel market growth in the region.

Key Market Players and Company Analysis

Several major pharmaceutical companies dominate the adult vaccine market, focusing on innovation and expansion:

1. GlaxoSmithKline plc.

   • Key vaccines: Arexvy, Shingrix, Infanrix
   • Recent Developments: Launched RSV vaccine (Arexvy) in 2023

2. AstraZeneca plc

   • Key vaccines: FluMist, COVID-19 vaccine
   • Recent Developments: Strengthening vaccine manufacturing capabilities

3. Sanofi Pasteur

   • Key vaccines: Fluzone, Adacel, Menactra
   • Recent Developments: Expanding global supply chains

4. Pfizer, Inc.

   • Key vaccines: Prevnar 20, Nimenrix, Trumenba
   • Recent Developments: Investing in pneumococcal vaccine research

5. Moderna, Inc.

   • Key vaccines: Spikevax, mRNA-1010 (Influenza vaccine in pipeline)
   • Recent Developments: Advancing mRNA technology for broader immunization

6. CSL Limited

   • Key vaccines: Afluria, Gardasil
   • Recent Developments: Enhancing flu vaccine distribution

Market Forecast (2024-2032)

Key Questions Answered in This Report

• How large is the adult vaccine market?
• What is the expected growth rate of the market?
• Which companies are leading in the adult vaccine industry?
• What are the major factors driving market expansion?
• Which region holds the largest market share?
• What are the key vaccine segments covered in the report?

Customization Services Available

• Market Size and Segmentation Analysis
• Additional Company Profiles (Up to 10 without extra cost)
• Country-Specific Market Reports
• Market Entry Strategy Consultation
• Trade and Production Insights

Final Thoughts

The global adult vaccine market is poised for robust growth, driven by increasing disease prevalence, government initiatives, and technological advancements. With continuous innovations in vaccine development and rising awareness about adult immunization, the market is set to expand significantly by 2032.